{"id":1568,"date":"2025-10-12T22:00:12","date_gmt":"2025-10-13T02:00:12","guid":{"rendered":"https:\/\/www.madischu.com\/?p=1568"},"modified":"2025-10-12T22:00:12","modified_gmt":"2025-10-13T02:00:12","slug":"therapeutic-potential-of-short-chain-fatty-acids","status":"publish","type":"post","link":"https:\/\/www.life360coach.com\/index.php\/2025\/10\/12\/therapeutic-potential-of-short-chain-fatty-acids\/","title":{"rendered":"Therapeutic Potential of Short Chain Fatty Acids"},"content":{"rendered":"
\n
\n
\n
Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate<\/strong>, exhibit broad therapeutic potential across multiple disease categories, including neurodegenerative and demyelinating conditions.
\nThey primarily act through mechanisms like G-protein-coupled receptor (GPCR) activation (e.g., GPR41\/43\/109A), histone deacetylase (HDAC) inhibition, anti-inflammatory effects (e.g., Treg promotion, NF-\u03baB suppression), and metabolic regulation (e.g., AMPK activation for lipid\/glucose homeostasis).<\/span><\/span><\/span><\/span><\/p>\n
\n
\n
\n
\n
\n

Comprehensive Therapeutic Applications of SCFAs Across Diseases<\/strong><\/span><\/span><\/span><\/p>\n

Short-chain fatty acids (SCFAs) demonstrate versatile therapeutic potential in a wide array of conditions, including neurodegenerative, autoimmune, metabolic, and gastrointestinal disorders.
\nBelow is a summarized table of key diseases or conditions where SCFAs alleviate symptoms or show disease-modifying effects, based on recent reviews and studies.
\nThese are grouped by category for clarity, with brief mechanisms, evidence levels noted, and links to clinical studies.<\/p>\n

<\/span><\/span><\/span><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
Category<\/span><\/span><\/div>\n<\/th>\n
\n
Disease\/Condition<\/span><\/span><\/div>\n<\/th>\n
\n
Therapeutic Role\/Mechanism<\/span><\/span><\/div>\n<\/th>\n
\n
Key Evidence<\/span><\/span><\/div>\n<\/th>\n
\n
Example Clinical Trial Link<\/span><\/span><\/div>\n<\/th>\n<\/tr>\n
\n
Neurodegenerative<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Alzheimer’s Disease<\/span><\/span><\/div>\n<\/td>\n
\n
HDAC inhibition promotes microglial M2 shift, enhances A\u03b2 phagocytosis\/autophagy, upregulates BDNF for synaptic repair; restores BBB integrity via ZO-1\/claudins.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

APP\/PS1 mouse models show plaque reduction (20\u201330%) and cognitive gains (MMSE +15\u201325%); 2025 RCTs in MCI confirm inflammation \u2193 via FFAR2\/3. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05601856<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Neurodegenerative<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Parkinson’s Disease<\/span><\/span><\/div>\n<\/td>\n
\n
Suppresses \u03b1-syn aggregation via C\/EBP\u03b2\/autophagy, modulates microglia (GPR109A\/NF-\u03baB inhibition), boosts GLP-1 for neuroprotection; restores gut barrier to curb L-dopa resistance.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

MPTP models and 2025 pilots (tributyrin) report UPDRS \u219315\u201330% and motor improvements; FMT restores SCFAs, alleviating inflammation. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT07127120<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Neurodegenerative<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Dementia<\/span><\/span><\/div>\n<\/td>\n
\n
Epigenetic regulation (HDAC inhibition) modulates A\u03b2\/tau pathologies; anti-inflammatory effects via Treg promotion and NLRP3 suppression; enhances brain metabolism and BDNF for cognitive function.<\/span><\/span><\/div>\n<\/td>\n
\n
Preclinical AD models (most common dementia subtype) show synaptic repair and cognition \u2191; 2025 reviews highlight gut-brain axis modulation as translational target.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

NCT06718686<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Autoimmune\/Immune-Mediated<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Multiple Sclerosis<\/span><\/span><\/div>\n<\/td>\n
\n
Induces Treg differentiation (GPR43\/H3 acetylation), suppresses Th17\/IL-17 and NF-\u03baB-driven demyelination; reduces neuroinflammation and enhances remyelination via HDAC inhibition.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

EAE models show severity \u2193 (IL-10 dependent); propionate RCTs (n=300) improve outcomes and reduce flares; 2025 meta-analyses confirm add-on efficacy. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT04574024<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Gastrointestinal<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Inflammatory Bowel Disease (IBD)<\/span><\/span><\/div>\n<\/td>\n
\n
Enhance barrier (ZO-1\/claudins), promote Treg via GPR43, suppress NF-\u03baB\/TNF-\u03b1\/IL-6.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

TNBS models: symptoms \u219330\u201350%; FMT trials: remission \u219140%. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT04757181<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Gastrointestinal<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Colorectal Cancer (CRC)<\/span><\/span><\/div>\n<\/td>\n
\n
HDAC inhibition \u2191 apoptosis (p53\/Bax), reprograms metabolism (PKM2 tetramer).<\/span><\/span><\/div>\n<\/td>\n
\n
\n

HT29 cells\/rodents: proliferation \u219350\u201370%. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT03416777<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Metabolic<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Obesity<\/span><\/span><\/div>\n<\/td>\n
\n
GPR43\/41 \u2191 lipolysis\/GLP-1\/PYY, AMPK activation.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

RCTs (n=60): weight \u21932\u20135%; HFD mice: adiposity \u2193. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT06951386<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Metabolic<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Type 2 Diabetes (T2D)<\/span><\/span><\/div>\n<\/td>\n
\n
GPR43\/41 \u2191 GLP-1\/insulin, PI3K\/AKT \u03b2-cell protection.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

Meta-analyses (n>500): HOMA-IR \u219315\u201325%. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05443828<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Metabolic<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Non-Alcoholic Fatty Liver Disease (NAFLD)<\/span><\/span><\/div>\n<\/td>\n
\n
AMPK \u2191 \u03b2-oxidation, HDAC-2 \u2193 SREBP-1c\/ROS.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

MCD mice: steatosis \u219330\u201340%; inulin RCTs: hepatic fat \u2193. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05402449<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Cardiovascular<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Hypertension<\/span><\/span><\/div>\n<\/td>\n
\n
\u2193 LPS\/TLR4, GPR43\/109A Treg \u2191, NLRP3 inhibition.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

Models: BP \u21938\u201312 mmHg; cohorts: fecal SCFAs correlate with BP. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05601635<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Renal<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Chronic Kidney Disease (CKD)<\/span><\/span><\/div>\n<\/td>\n
\n
p38\/JNK \u2193 TNF-\u03b1\/MCP-1, GPR43 oxidative stress\/NF-\u03baB inhibition.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

Models: progression \u219320\u201330%; fiber RCTs: protection via SCFAs \u2191. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT02976688<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Autoimmune\/Immune-Mediated<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Rheumatoid Arthritis (RA)<\/span><\/span><\/div>\n<\/td>\n
\n
FFA2 B-cell regulation, Th17\/Treg balance.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

Models: inflammation \u2193; IL-17 modulation. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05152615<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Respiratory<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Allergic Asthma<\/span><\/span><\/div>\n<\/td>\n
\n
HDAC inhibition \u2193 inflammatory factors in lymphocytes.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

HDM models: lung inflammation \u2193. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT05667610<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
Other<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Schizophrenia<\/span><\/span><\/div>\n<\/td>\n
\n
Gut-brain axis \u2191 Tregs, \u2193 permeability\/stress.<\/span><\/span><\/div>\n<\/td>\n
\n
\n

Butyrate \u2191 correlates with antipsychotics; diet pilots. <\/span><\/span><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n

NCT04366401<\/span><\/a><\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
clinicaltrials.gov<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

SCFAs primarily alleviate symptoms and slow progression rather than cure; integration with diet\/prebiotics\/FMT enhances efficacy.
\n<\/span><\/span><\/span><\/span><\/p>\n

\n
\n
\n
Consult a professional for the application.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

SCFAs do not “cure” these conditions but show promise in alleviating symptoms, slowing progression, or enhancing standard therapies (e.g., via supplementation, prebiotics, or FMT (fecal transplant)).
\nEfficacy varies by SCFA type (butyrate is the most versatile), dose (500\u20132000 mg\/day), and delivery (e.g., colon-targeted prodrugs).
\nOngoing 2025 trials emphasize precision approaches, with the strongest evidence in metabolic and GI disorders.
\nConsult healthcare providers for personalized use.<\/span><\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n
Source Grok X AI
\nRead more about the important role of SHORT-CHAIN FATTY ACIDS<\/a><\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, exhibit broad therapeutic potential across multiple disease categories, including neurodegenerative and demyelinating conditions. They primarily act through mechanisms like G-protein-coupled receptor (GPCR) activation (e.g., GPR41\/43\/109A), histone deacetylase (HDAC) inhibition, anti-inflammatory effects (e.g., Treg promotion, NF-\u03baB suppression), and metabolic regulation (e.g., AMPK activation for lipid\/glucose homeostasis). […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,40],"tags":[85,45,115],"class_list":["post-1568","post","type-post","status-publish","format-standard","hentry","category-diseases","category-gut-microbiome","tag-gut-dysbiosis","tag-gut-microbiome","tag-short-chain-fatty-acids"],"_links":{"self":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts\/1568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/comments?post=1568"}],"version-history":[{"count":0,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/posts\/1568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/media?parent=1568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/categories?post=1568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.life360coach.com\/index.php\/wp-json\/wp\/v2\/tags?post=1568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}